Leexone-TZ Injection is a potent combination antibiotic formulation containing Ceftriaxone 1000 mg and Tazobactam 125 mg, designed for the treatment of a wide spectrum of bacterial infections. Ceftriaxone, a third-generation cephalosporin, exhibits broad-spectrum bactericidal activity by inhibiting bacterial cell wall synthesis, while Tazobactam, a beta-lactamase inhibitor, enhances efficacy by preventing the enzymatic degradation of Ceftriaxone by beta-lactamase-producing organisms. This synergistic combination is effective against various Gram-positive and Gram-negative pathogens, including resistant strains. Leexone-TZ Injection is indicated for severe infections such as lower respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections, septicemia, and bone and joint infections. The injectable formulation allows for rapid systemic distribution, making it suitable for hospitalized patients requiring parenteral therapy. Dosage and duration of treatment should be determined based on the severity of infection, patient condition, and susceptibility patterns. Caution is advised in patients with known hypersensitivity to cephalosporins or penicillins. Adverse effects may include local injection site reactions, gastrointestinal disturbances, and hypersensitivity reactions. Proper administration and adherence to prescribed dosing regimens are essential to optimize therapeutic outcomes and minimize resistance development.